ArticleInternational journal of nanomedicine2020
A GSH-Responsive Nanoprodrug System Based on Self-Assembly of Lactose Modified Camptothecin for Targeted Drug Delivery and Combination Chemotherapy.
Article in International journal of nanomedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 32 citations in OpenAlex.
- Reductant-Responsive Squalene Dual-Prodrug Nanoparticles Co-Delivering Doxorubicin and Exatecan for Synergistic Breast Tumor Therapy.Pharmaceutics · 2026Article
- Engineering Strategies for Plant-Derived Extracellular Vesicles: Modification, Drug Delivery Performance, and Synergistic Effects with Gel Composite Systems.Pharmaceutics · 2026Review
- MnOPharmaceutics · 2026Article
- Mitochondria-Targeted MPDA Nanosystem Co-Delivering Evodiamine and IR820 for Chemo-Photothermal Therapy of Hepatocellular Carcinoma.International journal of nanomedicine · 2026Article
- Tromethamine‑Modified Chlorambucil Prodrug Nano-Micelles: Improved Colloidal Stability and Antitumor Efficacy.International journal of nanomedicine · 2026Article
- Multivalently engineered glyco-nanoplatforms for targeted therapy and diagnostics.Chemical science · 2025Review
- Prodrug nanosystem equipped with a sonosensitizer for combined chemotherapy and sonodynamic therapy of melanoma.Materials today. Bio · 2025Article
- Controlling Assembly of Hybrid DNA Nanostructures into Higher-Order Structures via Hydrophobicity.Angewandte Chemie (International ed. in English) · 2025Article
- Research progress on nanotechnology of traditional Chinese medicine to enhance the therapeutic effect of osteoarthritis.Drug delivery and translational research · 2024Review
- A Paramagnetic Metal-Organic Framework Enhances Mild Magnetic Hyperthermia Therapy by Downregulating Heat Shock Proteins and Promoting Ferroptosis via Aggravation of Two-Way Regulated Redox Dyshomeostasis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Carrier-free nanoplatforms from natural plants for enhanced bioactivity.Journal of advanced research · 2023Review
- Reactive oxygen species activated by mitochondria-specific camptothecin prodrug for enhanced chemotherapy.Bosnian journal of basic medical sciences · 2022Article
- Galactosed and Reduction-Responsive Nanoparticles Assembled from Trimethylchitosan-Camptothecin Conjugates for Enhanced Hepatocellular Carcinoma Therapy.Pharmaceutics · 2022Article
- Glyconanoparticles with Activatable Near-Infrared Probes for Tumor-Cell Imaging and Targeted Drug Delivery.International journal of nanomedicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConventional chemotherapy using small molecular antitumor drugs suffers from several limitations, for instance poor water solubility, high toxicity, and lack of specificity. However, prodrugs constructed by covalent modification of anticancer drugs can overcome these limitations, which are able to release its active form after entering the tumor tissues by specific stimulus response.
methodsA GSH-responsive glyco-nanoprodrug system has been constructed by self-assembled of amphiphilic lactosemodified camptothecin prodrug molecular (Lac-SS-CPT) for targeting drug delivery and combination therapy.
resultsUsing HL7702 cells as experimental models, the cytotoxic effects of Lac-SS-CPT were investigated to 10-30 µmol/L for 48 hours. Notably, the cell viability of Lac-SS-CPT to HL7702 cells was higher compared with free CPT which indicated that Lac-SS-CPT can reduce side-effects. Simultaneously, we have evaluated the anticancer efficiency of doxorubicin hydrochloride (DOX)-loaded Lac-SS-CPT glyco-nanoprodrug system (Lac-SS-CPT@DOX), where Lac-SS-CPT@DOX and free DOX incubated with HpeG2 cells and HL7702 cells for 24, 48, and 72 hours, respectively. It turned out that Lac-SS-CPT@DOX encapsulated anticancer drug (DOX) could decrease DOX side-effect on HL7702 cells and increase DOX anticancer efficiency. More importantly, the CPT and DOX were released from Lac-SS-CPT@DOX in HepG2 cells where a higher GSH concentration exists. Moreover, combination therapy efficiency was evaluated, where free DOX and Lac-SS-CPT@DOX incubated with DOX-resistance HepG2 cells (HepG2-ADR cells), respectively.
conclusionThe results revealed that the Lac-SS-CPT@DOX could enhance the cytotoxicity of DOX for HepG2-ADR cells and provided a new idea for designing an advanced nano-prodrug system toward combination therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.